Biotech’s public markets showed renewed activity as Agomab Therapeutics and Eikon Therapeutics raised capital in recent IPOs, and industry reporting highlighted four drugmakers that went public in a single week, raising close to $1 billion combined. BioCentury reported that Eikon and Agomab raised roughly $350 million between them but saw aftermarket weakness; STAT summarized the broader group of new listings that include SpyGlass and Veradermics and noted a resurgence in biotech IPO issuance. The flurry signals improving investor appetite for clinical‑stage biotechs after multi‑year doldrums, though patchy aftermarket performance underscores ongoing volatility in valuations and execution risk for newly public drug developers.